Pharmaceuticals
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity Opaganib's unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect agai...
2021-06-28 19:00
11617
InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL
BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the trea...
2021-06-28 16:02
10457
Qbiotics concludes successful $85 million capital raise
* Capital raise nets $85 million from Existing Shareholders, Existing Institutional Investors, and cornerstone investor TDM Growth Partners. * Funding to enable human clinical development of the Company's anticancer drug candidate tigilanol tiglate and its wound healing drug candidate EBC-1013...
2021-06-28 09:36
2651
CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer
* Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) * In March 2021, GAVRETO was approved by the National Medical Products Administration (NMPA) ofChina for the treatment of patie...
2021-06-28 08:05
4792
Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery
SHANGHAI, June 26, 2021 /PRNewswire/ -- Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and ...
2021-06-26 23:00
3455
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
SHANGHAI and GAITHERSBURG, Md., June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China N...
2021-06-25 20:00
16334
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China
BEIJING, June 25, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today thatChina's National Medical Products Administration (NMPA) has approved the initiation of a Phase I clinical trial of ICP-033, the Compan...
2021-06-25 19:04
16192
HistoIndex's AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo
SINGAPORE, June 25, 2021 /PRNewswire/ -- HistoIndex
2021-06-25 18:30
2148
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003
HANGZHOU, China, June 25, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative drug development company, announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (...
2021-06-25 15:11
3650
Zuellig Pharma Selects CYFIRMA to Elevate Cyber-intelligence Capabilities and Strengthen Cybersecurity Posture
SINGAPORE, June 25, 2021 /PRNewswire/ -- CYFIRMA, a threat discovery and
cyber-intelligence platform company, funded by Goldman Sachs, Zodius Capital
and Z3Partners, today announced thatZuellig Pharma
2021-06-25 12:57
2002
Samsung Biologics Issues Its First Annual Sustainability Report
* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...
2021-06-25 09:01
22556
Bridge Biotherapeutics Integrates CDD Vault Collaborative Database Solution into Its R&D Platform to Harmonize Research and Drug Discovery Project Management
- Bridge has been enhancing its research and drug discovery engines by efficiently managing scientific assets on a collaborative database solution - CDD provides a secure research database platform enabling seamless collaboration between drug discovery and development teams that are in different...
2021-06-25 05:57
2203
Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE
NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has completed its Series B financing, raisingUS$ 50 million (RMB 330 million). This round of investment was co-led by Matrix Partners China and CPE, with participation from S...
2021-06-25 00:26
2970
Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE
NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has completed its Series B financing, raisingUS$ 50 million (RMB 330 million). This round of investment was co-led by Matrix Partners China and CPE, with participation from Shan...
2021-06-24 20:43
2758
Boan Biotech Publishes Research Results for CEA/CD3 Bispecific Antibody in Antibody Therapeutics
BOSTON, June 24, 2021 /PRNewswire/ -- Luye Pharma Group's subsidiary Boan
Biotech recently published research results for its innovative in-house
bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) inAntibody
Therapeutics.
2021-06-24 14:49
3354
China's first CAR-T Cell Therapy approved-Fosun Kite Axicabtagene Ciloleucel (FKC876)
* The first* CAR-T cell therapy approved by NMPA: opening a new era of cell therapy inChina * Individualized living-cell-based medicine: genetically modify patient's T-cells to expresses a chimeric antigen receptor (CAR) that will activate T-cells upon engaging cells carrying the specific ant...
2021-06-24 14:46
2154
CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication application
* Key efficacy data showed that GAVRETO demonstrated deep and durable clinical activity in Chinese patients with RET fusion-positive non-small cell lung cancer (NSCLC) * CStone plans to submit new indication application to the China National Medical Products Administration for GAVRETO as a fi...
2021-06-24 08:05
6040
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Highlights: * Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. * Concurrence with Alterity's plan to target early stage MSA patients. * Endorsement on selection ...
2021-06-23 21:21
14865
Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections
* Samsung Biologics' Live Virtual Tour (LVT) used in one of the earliest FDA full virtual assessments * Recently hosted EMA for 6 PAIs simultaneously using LVT INCHEON, South Korea ,June 23, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (C...
2021-06-23 19:28
1374
Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars
BEIJING, June 23, 2021 /PRNewswire/ -- Biocytogen
2021-06-23 17:02
2276
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9236
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7714